Mikafungin Accord (Micafungin)

Micafungin inhibits the fungal enzyme 1,3‑β‑D‑glucan synthase, which is essential for synthesising 1,3‑β‑D‑glucan, a key structural component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, causing osmotic instability and leading to fungal cell death.

The dosing regimen for Mikafungin Accord is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. The product is supplied as an injectable solution for intravenous infusion under medical supervision.

Safety data for micafungin in pregnancy and lactation are limited. The product should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mikafungin Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Compared with azole antifungals such as fluconazole, micafungin offers a different mechanism—cell‑wall inhibition—resulting in activity against many azole‑resistant Candida species. Unlike other echinocandins, micafungin has a relatively low potential for drug‑drug interactions, but clinicians still assess individual patient factors when choosing therapy.

Mikafungin Accord must be stored refrigerated at 2 °C to 8 °C. The vial should be kept in its original packaging, protected from light, and should not be frozen or shaken. Prior to administration, the solution is reconstituted according to the product label and used within the recommended time frame.

The product is supplied as a sterile injectable solution for intravenous infusion. After reconstitution, the dose is diluted in an appropriate IV fluid and infused over the time period specified by the prescribing information, typically 30‑60 minutes, under clinical supervision.

Serious adverse events include severe hepatic injury, anaphylactic or severe hypersensitivity reactions, acute renal dysfunction, and significant hematologic abnormalities such as neutropenia. Patients should be monitored for signs of liver dysfunction, allergic reactions, and changes in renal or blood parameters throughout therapy.

Mikafungin Accord is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised in patients with severe hepatic impairment, and the drug should be avoided in pregnant women unless the expected benefit justifies the potential risk.